The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
The National Association of Chain Drug Stores is praising the Federal Trade Commission's (FTC) unanimous, 5-0, vote on Monday to release the second interim staff report on the FTC's study of big ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
Zacks.com on MSN11h
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
CVS Caremark, OptumRx and St. Louis-based Express Scripts — are part of huge health conglomerates that also own insurers, ...
The report is the latest indictment of America’s broken healthcare system.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback